Mixture-of-Recursions (MoR) is a new AI architecture that promises to cut LLM inference costs and memory use without ...

As of July 22, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI stocks to buy according to analysts. On July 8, ...

RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.

Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion Pharmaceuticals (NASDAQ: RXRX) surged by more than 12% by 11 a.m. ET today. The move is ...

Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

Investing.com -- Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock surged 11.5% while Rallybio Corp (NASDAQ: RLYB) shares jumped 35% Monday after Recursion acquired full rights to REV102, an oral ...

Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.

Rallybio (NASDAQ:RLYB) stock soars 114% after agreeing to sell its stake in a rare bone disorder asset, extending cash runway to mid-2027. Read more here.

Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...